Treatment of Desmoid Fibromatosis With Arterial Embolization
ConditionDesmoid Fibromatosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorIstituto Ortopedico Rizzoli
About this trial
Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. These studies report promising results through the use of chemoembolization, that is, arterial embolization using particles loaded with chemotherapy.
Instead, the type of treatment we propose would consist of injection of embolizing material without the use of chemotherapy, based on the positive results we have consistently reported over the years on arterial embolization of musculoskeletal tumors.
Eligibility criteria
Qualifiers
Patients of both sexes aged ≥ 12 years
Fibromatosis demsoid symptomatic and in active phase (documented growth at last follow-ups)
Patients not eligible for surgery or cryoablation
Patients who have had embolization surgery for fibromatosis desmoide from 01/01/2023 to date and all new patients listed for this type of treatment.
Disqualifiers
Patients with life expectancy <3 months or severely impaired status functional status (ASA 4)
Patients with fibromatosis not in active phase, documented clinically and by investigations imaging (MRI, CT)
Patients with coagulation deficiency or plateletopenic disease
Patients with documented active infection
Trial design
Treatments tested in this trial
- embolization therapy
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov